# Bilirubin Blood Test Market

> Bilirubin Blood Test Market Research Report Information by Test Type (Total Serum Bilirubin), Product Type (Consumables and Instruments), Applications (Pediatric/Infants and Adults), End User (Hospitals, Pediatric Clinics) and Region (North America, Europe, Asia Pacific and Rest of the World (RoW)) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.63%
- **2024:** $ 1.25 Billion
- **2025:** $ 1.33 Billion
- **2035:** $ 2.53 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific(US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Mindray Medical International (CN), Sysmex Corporation (JP), Bio-Rad Laboratories (US)

**Report ID:** MRFR/LS/0249-CR · **Pages:** 148 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/bilirubin-blood-test-market-720

---

## Market Summary

As per Market Research Future analysis, the Bilirubin Blood Test Market Size was estimated at 1.248 USD Billion in 2024. The Bilirubin Blood Test industry is projected to grow from USD 1.33 Billion in 2025 to USD 2.528 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.63% during the forecast period 2025 - 2035

## Market Drivers

### Rising Incidence of Liver Diseases

The increasing prevalence of liver diseases, such as hepatitis and cirrhosis, is a primary driver for the Bilirubin Blood Test Market. According to health statistics, liver diseases have shown a notable rise, leading to a heightened demand for diagnostic tests. This trend is likely to continue as more individuals seek medical attention for liver-related issues. The Bilirubin Blood Test Market serves as a crucial tool in diagnosing and monitoring these conditions, thereby propelling market growth. Furthermore, the aging population is more susceptible to liver diseases, which may further amplify the demand for bilirubin testing. As healthcare providers emphasize early detection and management of liver diseases, the Bilirubin Blood Test Market is expected to expand significantly.

### Growing Focus on Preventive Healthcare

The shift towards preventive healthcare is significantly influencing the Bilirubin Blood Test Market. As individuals become more health-conscious, there is a growing emphasis on regular health screenings, including liver function tests. Preventive measures are increasingly recognized as essential for early detection of potential health issues, including liver dysfunction. This trend is supported by various health organizations advocating for routine screenings, which may lead to an increase in bilirubin testing. The market is likely to benefit from this proactive approach, as healthcare providers recommend bilirubin tests as part of comprehensive health assessments. Consequently, the Bilirubin Blood Test Market is poised for growth as preventive healthcare becomes a priority for both patients and providers.

### Regulatory Support for Diagnostic Testing

Regulatory support for diagnostic testing is a crucial factor influencing the Bilirubin Blood Test Market. Governments and health authorities are increasingly recognizing the importance of accurate diagnostic tools in managing public health. This recognition has led to the establishment of guidelines and frameworks that promote the use of bilirubin tests in clinical settings. Additionally, funding and support for research and development in diagnostic technologies are likely to enhance the availability and reliability of bilirubin testing. As regulatory bodies continue to advocate for improved diagnostic practices, the market for bilirubin blood tests is expected to grow, driven by the need for effective monitoring of liver health.

### Technological Innovations in Diagnostic Testing

Technological advancements in diagnostic testing methodologies are transforming the Bilirubin Blood Test Market. Innovations such as point-of-care testing and automated laboratory systems enhance the accuracy and efficiency of bilirubin testing. These advancements not only improve patient outcomes but also streamline laboratory workflows, making testing more accessible. The introduction of portable devices allows for rapid testing in various settings, including outpatient clinics and home care. As healthcare systems increasingly adopt these technologies, the market for bilirubin blood tests is likely to experience substantial growth. Moreover, the integration of artificial intelligence in diagnostic processes may further refine testing accuracy, thereby increasing the reliance on bilirubin tests in clinical practice.

### Increased Awareness of Jaundice and Its Implications

The rising awareness of jaundice and its implications is driving the demand for bilirubin testing within the Bilirubin Blood Test Market. Educational campaigns and health initiatives have contributed to a better understanding of jaundice symptoms and the importance of timely diagnosis. As more individuals recognize the signs of jaundice, they are more likely to seek medical evaluation, leading to an increase in bilirubin tests. This heightened awareness is particularly evident among parents, as neonatal jaundice is a common concern. The emphasis on early detection and treatment of jaundice is likely to sustain the demand for bilirubin testing, thereby positively impacting the market.

## Future Outlook

The Bilirubin Blood Test Market is projected to grow at a 6.63% CAGR from 2025 to 2035, driven by increasing prevalence of liver diseases and advancements in diagnostic technologies.

**New opportunities:**

- Development of portable bilirubin testing devices for home use.
- 
- Integration of AI-driven analytics for enhanced diagnostic accuracy.
- Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)services for remote bilirubin testing and consultations.

By 2035, the market is expected to be robust, reflecting significant advancements and increased accessibility.

## Segment Insights

### By Test Type: Total Serum Bilirubin (Largest) vs. Direct/Conjugated Bilirubin Test (Fastest-Growing)

The Bilirubin Blood Test Market showcases a diverse range of test types, with Total Serum Bilirubin (TSB) leading in market share due to its broad application in diagnosing and monitoring liver function. In contrast, the Direct/Conjugated Bilirubin Test has demonstrated rapid growth, capturing attention for its precision in identifying specific liver disease conditions. Indirect/Unconjugated Bilirubin Tests, while essential, hold a smaller share compared to these two key segments. Overall, the distribution reflects the importance of comprehensive testing approaches in clinical practices. Growth trends indicate a significant shift towards more specialized testing, particularly in the Direct/Conjugated Bilirubin realm. Factors driving this trend include an increasing prevalence of liver-related disorders and rising awareness of diagnostic accuracy among healthcare professionals. Advances in technology and the development of point-of-care testing have further propelled the demand for these tests, making them integral to modern diagnostic protocols and leading to their rapid adoption in various clinical settings.

Total Serum Bilirubin (Dominant) vs. Direct/Conjugated Bilirubin Test (Emerging)

Total Serum Bilirubin (TSB) remains the dominant player in the Bilirubin Blood Test Market due to its versatility in assessing overall liver health and diagnosing various conditions, such as jaundice and liver disease. Its widespread acceptance in laboratories and clinics ensures a strong foothold in routine testing. Meanwhile, the Direct/Conjugated Bilirubin Test is emerging as a vital tool for pinpointing specific pathologies. Its precise measurement capabilities allow for better diagnosis and treatment monitoring. This segment's growth is fueled by an increasing demand for specificity in testing, driving innovation and adoption in clinical settings. Together, these segments illustrate a balanced market that caters to both broad screening needs and targeted diagnostic purposes.

### By Product Type: Consumables (Largest) vs. Instruments (Fastest-Growing)

In the Bilirubin Blood Test Market, the product type segment is characterized by a significant distribution of market share between consumables and instruments. Consumables, including test kits and reagents, constitute the largest segment, accounting for a substantial portion of the total market. Their widespread use in laboratories and healthcare facilities ensures a steady demand, as consumables are vital for carrying out bilirubin tests effectively. In contrast, the instruments segment, comprising the devices used for testing, is the fastest-growing. Innovations in technology and increasing healthcare needs are driving this segment's growth as newer, more efficient devices become available.

Product Type: Consumables (Dominant) vs. Instruments (Emerging)

In the Bilirubin Blood Test Market, consumables play a dominant role due to their essential nature in the testing process. They include a wide range of products such as test kits, reagents, and specimen collection devices, which are critical for accurate bilirubin testing. These consumables are often favored for their ease of use and cost-effectiveness, making them preferred choices in clinical settings. On the other hand, the instruments segment is emerging rapidly, driven by technological advancements in diagnostic devices. These instruments offer improved accuracy, automation, and faster results, making them increasingly desirable in modern laboratories. The growing preference for point-of-care testing is likewise contributing to the rise of this segment.

### By Application: Infants (Largest) vs. Adults (Fastest-Growing)

In the Bilirubin Blood Test Market, the application segment is significantly divided between infants and adults. The infant segment holds a substantial market share due to the rising incidence of neonatal jaundice, which necessitates timely testing and diagnosis. Furthermore, healthcare providers are increasingly aware of the importance of early detection, thereby propelling the demand for bilirubin testing in newborns.

Application: Infants (Dominant) vs. Adults (Emerging)

The infant segment is characterized by its higher prevalence of bilirubin testing, largely driven by the need to monitor jaundice in newborns. This segment has established itself as dominant in the market due to the critical nature of timely diagnosis in infants to prevent complications. Conversely, the adult segment is emerging rapidly, fueled by growing health awareness, aging demographics, and the rising prevalence of conditions like liver diseases. Adults are increasingly seeking bilirubin tests not only for jaundice but also as part of routine health check-ups, emphasizing the segment's potential for growth.

### By End-Users: Hospitals (Largest) vs. Pathological Labs (Fastest-Growing)

In the Bilirubin Blood Test Market, hospitals represent the largest segment, benefitting from their extensive patient base and integrated healthcare services. Following closely are pathological labs, which are essential for diagnostic testing and have been gaining market share due to the growing demand for early disease diagnosis. Other segments like research laboratories and pediatric clinics also contribute to the market but remain comparatively smaller in size. The growth trends in this segment are fueled by an increasing prevalence of liver diseases and a heightened focus on preventive healthcare. Technological advancements in diagnostic procedures and a rise in the number of accredited pathological labs have further propelled the demand for bilirubin blood tests. Additionally, heightened awareness of neonatal jaundice and the subsequent need for bilirubin testing in pediatric populations drive sustained growth in this area.

Pathological Labs (Dominant) vs. Pediatric Clinics (Emerging)

Pathological labs play a dominant role in the Bilirubin Blood Test Market, attributed to their focus on meticulous testing protocols and robust infrastructure capable of handling a high volume of tests. These facilities are equipped with advanced diagnostic technologies, ensuring accurate and rapid results which are critical in clinical decision-making. The growing incidence of liver-related diseases and advancements in lab technology bolster their market position. Meanwhile, pediatric clinics represent an emerging segment, driven by the increasing incidence of conditions like neonatal jaundice, which demands specialized care and timely testing. These clinics are tailored to cater to younger demographics, highlighting their importance in continuous health monitoring and early intervention strategies.

## Regional Market Share Analysis

### North America : Leading Innovation and Demand

North America is the largest market for bilirubin blood tests, holding approximately 45% of the global market share. The region's growth is driven by increasing incidences of liver diseases, advancements in diagnostic technologies, and supportive healthcare policies. Regulatory bodies like the FDA are facilitating faster approvals for innovative testing methods, further boosting market demand. The rising awareness of preventive healthcare is also contributing to the growth of this market. The United States is the primary contributor to this market, with significant investments in healthcare infrastructure and research. Key players such as Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific are leading the competitive landscape, focusing on product innovation and strategic partnerships. The presence of advanced healthcare facilities and a high prevalence of liver-related disorders are key factors driving the demand for bilirubin blood tests in this region.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for bilirubin blood tests, accounting for approximately 30% of the global market share. The region's growth is propelled by increasing healthcare expenditure, a rising geriatric population, and stringent regulations that ensure high-quality diagnostic products. The European Medicines Agency (EMA) plays a crucial role in regulating and approving new diagnostic technologies, which fosters innovation and market growth. Leading countries in this region include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced diagnostic solutions. The competitive landscape features major players like Siemens Healthineers and Bio-Rad Laboratories, who are investing in research and development to enhance their product offerings. The collaboration between public health organizations and private companies is also strengthening the market presence of bilirubin blood tests in Europe.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is witnessing rapid growth in the bilirubin blood test market, holding approximately 20% of the global market share. The region's expansion is driven by increasing healthcare investments, rising awareness of liver diseases, and a growing population. Countries like China and India are experiencing significant demand due to their large patient populations and improving healthcare infrastructure. Government initiatives aimed at enhancing healthcare access are also contributing to market growth. China is the largest market in this region, followed by India and Japan. The competitive landscape is characterized by the presence of both global and local players, including Mindray Medical International and Sysmex Corporation. These companies are focusing on expanding their product portfolios and enhancing distribution networks to capture a larger market share. The increasing prevalence of liver disorders in these countries is further driving the demand for bilirubin blood tests.

### Middle East and Africa : Emerging Market Potential

The Middle East and Africa region is gradually emerging in the bilirubin blood test market, holding about 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising awareness of liver diseases, and the expansion of healthcare facilities. Governments in several countries are implementing policies to improve healthcare access, which is expected to boost the demand for diagnostic tests, including bilirubin blood tests. Leading countries in this region include South Africa and the UAE, where healthcare systems are evolving rapidly. The competitive landscape is still developing, with both local and international players vying for market share. Companies are focusing on establishing partnerships and collaborations to enhance their market presence. The increasing prevalence of liver-related disorders in these countries is expected to drive further growth in the bilirubin blood test market.

## Competitive Benchmarking

The Bilirubin Blood Test Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for accurate diagnostic tools and advancements in technology. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its product portfolio through continuous research and development, while Roche Diagnostics (CH) emphasizes partnerships with healthcare providers to improve diagnostic accuracy. Siemens Healthineers (DE) is investing in digital transformation initiatives, aiming to integrate AI and machine learning into their testing processes, thereby enhancing operational efficiency and patient outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes technological advancement and customer-centric solutions.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in the context of the Bilirubin Blood Test Market, which is moderately fragmented, with several players vying for market share. The collective influence of these key players shapes the market structure, as they engage in strategic collaborations and optimize their supply chains to meet the growing demand for bilirubin testing.
In August 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading telehealth provider to enhance remote bilirubin testing capabilities. This collaboration is significant as it aligns with the growing trend of telemedicine, allowing for more accessible and timely diagnostics, particularly in underserved regions. By integrating their testing solutions with telehealth platforms, Roche aims to expand its reach and improve patient outcomes, thereby solidifying its position in the market.
In September 2025, Siemens Healthineers (DE) launched a new AI-driven bilirubin testing device that promises to reduce testing time and improve accuracy. This innovation is crucial as it addresses the increasing demand for rapid diagnostics in clinical settings. The introduction of this device not only enhances Siemens' product offerings but also positions the company as a leader in the integration of AI technology within the diagnostic space, potentially reshaping competitive dynamics in the market.
In July 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in Asia to meet the rising demand for bilirubin tests in emerging markets. This strategic move is indicative of Abbott's commitment to localizing production and optimizing its supply chain. By establishing a stronger presence in Asia, Abbott is likely to enhance its competitive edge, catering to the specific needs of regional markets while reducing lead times and costs associated with international shipping.
As of October 2025, the Bilirubin Blood Test Market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and deliver high-quality, efficient diagnostic solutions.

## Report Scope

| MARKET SIZE 2024 | 1.248(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.33(USD Billion) |
| MARKET SIZE 2035 | 2.528(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.63% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Mindray Medical International (CN), Sysmex Corporation (JP), Bio-Rad Laboratories (US) |
| Segments Covered | Test Type |
| Key Market Opportunities | Integration of advanced diagnostic technologies enhances accuracy in the Bilirubin Blood Test Market. |
| Key Market Dynamics | Rising demand for early disease detection drives innovation and competition in the Bilirubin Blood Test market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Bilirubin Blood Test Market by 2035?**
A: The Bilirubin Blood Test Market is projected to reach a valuation of 2.528 USD Billion by 2035.

**Q: What was the market valuation of the Bilirubin Blood Test Market in 2024?**
A: In 2024, the market valuation of the Bilirubin Blood Test Market was 1.248 USD Billion.

**Q: What is the expected CAGR for the Bilirubin Blood Test Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Bilirubin Blood Test Market during the forecast period 2025 - 2035 is 6.63%.

**Q: Which companies are considered key players in the Bilirubin Blood Test Market?**
A: Key players in the Bilirubin Blood Test Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.

**Q: What are the main segments of the Bilirubin Blood Test Market?**
A: The main segments of the Bilirubin Blood Test Market include Test Type, Product Type, Application, and End-Users.

**Q: What was the market size for Total Serum Bilirubin (TSB) in 2024?**
A: The market size for Total Serum Bilirubin (TSB) was 0.624 USD Billion in 2024.

**Q: How much is the market for Direct/Conjugated Bilirubin Test expected to grow by 2035?**
A: The market for Direct/Conjugated Bilirubin Test is expected to grow to 0.748 USD Billion by 2035.

**Q: What is the projected market size for Consumables in the Bilirubin Blood Test Market by 2035?**
A: The projected market size for Consumables in the Bilirubin Blood Test Market is anticipated to reach 1.528 USD Billion by 2035.

**Q: Which end-users are expected to drive growth in the Bilirubin Blood Test Market?**
A: End-users such as hospitals, diagnostics centers, and pathological labs are expected to drive growth in the Bilirubin Blood Test Market.

**Q: What is the expected market size for the Indirect/Unconjugated Bilirubin Test by 2035?**
A: The expected market size for the Indirect/Unconjugated Bilirubin Test is projected to reach 0.532 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bilirubin-blood-test-market-720*